Rigel Pharmaceuticals, Inc.

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel announced new GAVRETO (pralsetinib) data to be presented at ESMO Congress 2026 in Madrid, including a rapid oral session on pooled ARROW and TAPISTRY analysis in RET fusion-positive solid tumors. The pooled analysis of 49 patients showed a 53% overall response rate with 12.2 months median duration of response, including an 88% ORR in previously-treated pancreatic tumors. Thyroid cancer patients showed an 81.3% ORR, and first-line NSCLC patients on pralsetinib had a 75% ORR versus 26% on prior standard of care. The data support potential tumor-agnostic and first-line use of pralsetinib, though Rigel cautions the analyses involve small, selected populations and may not predict broader outcomes.

•13d ago

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals announced that VEPPANU (vepdegestrant), the first and only FDA-approved PROTAC, is now available by prescription in the U.S. for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. The drug is priced at $29,400 per 30-day supply and is immediately available through specialty distributors and pharmacies, with patient support programs offered via RIGEL ONECARE. The commercial launch follows an exclusive global license agreement with Arvinas and Pfizer, marking a significant milestone in Rigel's transition to a commercial-stage company.

•2mo ago

Rigel Reports Second Quarter 2026 Financial Results

Rigel reported Q2 2026 total revenue of $78.7 million, driven by a 14% year-over-year increase in net product sales to $67.0 million, and achieved net income of $17.3 million. Management raised full-year 2026 revenue guidance to $285 million to $295 million, citing strong commercial performance and increased collaboration revenue expectations. The company expanded its portfolio by in-licensing VEPPANU from Arvinas and Pfizer for a $70 million upfront payment, with U.S. commercial availability expected in mid-August, while the R289 Phase 1b study remains on track for dose selection in the second half of 2026.

•2mo ago

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

Rigel Pharmaceuticals appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer, M.D. Hannah, a board member since 2021, resigned from the board to assume the executive role. Dr. Hannah brings extensive oncology drug development experience, including roles at CytomX Therapeutics and SUGEN. She joins Rigel as the company advances its lead asset R289 through a Phase 1b study for lower-risk MDS, with preliminary data expected by the end of 2026. The company remains on track to select a recommended Phase 2 dose for R289 in the second half of 2026. Rigel is also evaluating additional indications for R289 and progressing the development of vepdegestrant for metastatic breast cancer.

•4mo ago

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Pharmaceuticals closed the exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant) following the expiration of the HSR waiting period. Rigel remitted the $70 million upfront payment to its partners and expects to make the therapy commercially available in August. VEPPANU is an FDA-approved treatment for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.

•4mo ago

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel will present final Phase 3 data for GAVRETO (pralsetinib) in RET fusion-positive NSCLC at the ASCO Annual Meeting, where the drug met its primary PFS endpoint and showed superior response rates versus standard of care. The company also highlighted real-world data for REZLIDHIA (olutasidenib) in relapsed/refractory AML, showing a 60.8% CR/CRh rate and median response duration of 30.3 months in patients previously treated with venetoclax. These presentations underscore the clinical utility of Rigel’s oncology portfolio, with GAVRETO reinforcing its first-line position and REZLIDHIA validating its role in later-line treatment sequencing.

•5mo ago